Results 51 to 60 of about 7,838 (234)

Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double‐blind meal test early‐phase study

Diabetes, obesity and metabolism, 2021
To compare the pharmacokinetics (PK), glucodynamics (GD), and tolerability following single and multiple daily subcutaneous (SC) doses of ultra rapid lispro (URLi) and Humalog® in patients with type 1 diabetes mellitus (T1D).
C. Kazda, J. Leohr, Rong Liu, S. Reddy, M. Dellva, M. Loh, T. Hardy, L. Plum-Mörschel   +7 more
semanticscholar   +1 more source

Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes [PDF]

, 2004
Objectives: To assess the clinical and cost-effectiveness of continuous subcutaneous insulin infusion (CSII) compared with multiple daily injections (MDI) in the delivery of intensive insulin therapy for the treatment of diabetes mellitus.
Green, C., N Waugh, Waugh, Norman, M Sidhu, D Hartwell, Colquitt, J. L. (Jill L.), Hartwell, D. (Debbie L.), C Green, J Colquitt, Sidhu, M. K.   +9 more
core   +1 more source

South Asian Consensus Guideline: Use of insulin in diabetes during Ramadan

Indian Journal of Endocrinology and Metabolism, 2012
A person with diabetes mellitus (DM) has every right to perform the ritual of fasting during Ramadan. In daily practice we come across both type 1 and type 2 DM who wish to fast.
Md Faruque Pathan, Rakesh Kumar Sahay, Abdul Hamid Zargar, Syed Abbas Raza, A K Azad Khan, Mohammed Ashraf Ganie, Nazrul Islam Siddiqui, Firoz Amin, Osama Ishtiaq, Sanjay Kalra   +9 more
doaj   +1 more source

Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study

Diabetes, obesity and metabolism, 2020
To compare the pharmacokinetic (PK) and glucodynamic (GD) characteristics of ultra rapid lispro (URLi; Eli Lilly and Company, Indianapolis, Indiana), Fiasp® (Novo Nordisk, Bagsvaerd, Denmark), Humalog® (Eli Lilly and Company) and NovoRapid® (Novo Nordisk)
T. Heise, H. Linnebjerg, D. Coutant, E. Labell, E. Zijlstra, C. Kapitza, J. Bue-Valleskey, Qianyi Zhang, M. Dellva, J. Leohr   +9 more
semanticscholar   +1 more source

Forum for injection techniques, India: The first Indian recommendations for best practice in insulin injection technique

Indian Journal of Endocrinology and Metabolism, 2012
Advances in the treatment of diabetes have led to an increase in the number of injectable therapies, such as human insulin, insulin analogues, and glucagon-like peptide-1 analogues.
Sanjay Kalra, Yatan Pal Singh Balhara, Manash P Baruah, Manoj Chadha, Hemraj B Chandalia, Subhankar Chowdhury, K M Prasanna Kumar, Sonal Modi, Shailesh Pitale, Rishi Shukla, Rakesh Sahay, Annamalai Sundaram, Ambika G Unnikrishnan, Subhash K Wangnoo   +13 more
doaj   +1 more source

Assessment the equivalence of the bioanalogue insulin lizpro biphasic 25 (Geropharm-bio, Russia) and Humalog® Mix 25 (Lilly France, France) using the euglycemic hyperinsulinum clamp method on healthy volonters

Сахарный диабет, 2018
Background: Modern medicine requires use of effective antidiabetic drugs that can imitate the natural profile of insulin in the body of patients with diabetes mellitus.
Alexander Y. Mayorov, Ekaterina O. Koksharova, Ekaterina E. Mishina, Roman V. Drai, Olga I. Avdeeva, Igor E. Makarenko   +5 more
doaj   +1 more source

The DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) Trial Comparing the durability of lispro mix 75/25 and glargine [PDF]

, 2011
OBJECTIVE-This study compared the durability of glycemic control of twice-daily insulin lispro mix 75/25 (LM75/25: 75% insulin lispro protamine suspension/25% lispro) and once-daily insulin glargine, added to oral antihyperglycemic drugs in type 2 ...
Fahrbach, Jessie L., Jiang, Honghua H., Herman, William H., Wolffenbuttel, Bruce H. R.; id_orcid, Jiang, H. H., Fahrbach, J. L., Wolffenbuttel, Bruce H. R., Buse, John B., Martin, Sherry A., Stephen Hippler, Shenouda, Sylvia K., Bruce H.R. Wolffenbuttel, Hippler, Stephen, Martin, S. A., Herman, W. H., John B. Buse, William H. Herman, Shenouda, S. K., Sherry A. Martin, Wolffenbuttel, B. H. R., Jessie L. Fahrbach, Sylvia K. Shenouda, Hippler, S., Honghua H. Jiang, Buse, J. B.   +24 more
core   +1 more source

Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes [PDF]

, 2018
\ua9 Philip Home, et al., 2018; Published by Mary Ann Liebert, Inc. 2018. Background: SAR342434 (SAR-Lis) is a biosimilar (follow-on) of insulin lispro (Humalog\uae; Ly-Lis).
Home P, Wernicke-Panten K, Kirchhein Y, Ziemen M, Pierre S, Derwahl K-M, Garg SK   +6 more
core   +4 more sources

Ultra rapid lispro (URLi) shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early‐phase study

Diabetes, obesity and metabolism, 2021
To compare the pharmacokinetics (PK), glucodynamics (GD) and tolerability following single and multiple daily subcutaneous doses of ultra rapid lispro (URLi) and Humalog® in patients with type 2 diabetes mellitus (T2D).
J. Leohr, C. Kazda, Rong Liu, S. Reddy, M. Dellva, M. Matzopoulos, M. Loh, T. Hardy, O. Klein, C. Kapitza   +9 more
semanticscholar   +1 more source

Management of Diabetes Mellitus with Insulin Lispro

, 2011
Insulin lispro (Humalog®) is a recombinant human insulin analogue with reversed amino acids at position 28 and 29 on the insulin B-chain (Lys(B28), Pro(B29)).
Masami Tanaka, Hiroshi Itoh
core   +1 more source